Conjugated linoleic acid (CLA)
Also called: CLA, conjugated linoleic acid isomers, CLA-rich oil
A mixture of linoleic acid isomers with conjugated double bonds, found mainly in dairy products and beef. Supplements supply it as a triacylglycerol or free fatty acid, mainly the c9,t11 and t10,c12 isomers; Health Canada describes supplement CLA as synthetic.
- Category
- Fatty acid
- Forms
- CLA-rich oil (triacylglycerol or free fatty acid forms); Health Canada specification: total CLA at least 78%, c9,t11 and t10,c12 isomers each at least 36%
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2024 meta-analysis included 70 RCTs (96 effect sizes, 4,159 adults; 69 RCTs in its results text) comparing CLA supplementation with placebo. It did not exclude combination products; at least one included trial combined CLA with γ-oryzanol. [2]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBlood sugar and weight2 topics
CHeart and blood vessels1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Body weight and body fat in adults | B | A 2024 meta-analysis of 70 RCTs (4,159 adults) found CLA lowered body mass by 0.35 kg and fat mass by 0.44 kg versus control; in high-quality trials, fat mass and body fat percentage did not change. [2] |
| Long-term weight in overweight and obesity | B | A 2012 meta-analysis of 7 RCTs lasting at least 6 months found 0.70 kg more weight loss and 1.33 kg more fat loss than placebo; the authors judged clinical relevance uncertain, and four trials had serious reporting flaws. [3] |
| Blood lipids | C | NIH ODS states CLA might adversely affect lipid profiles, although study results are inconsistent; some isomers may lower HDL cholesterol and raise lipoprotein(a). [4] |
Main constituents: CLA isomers c9,t11 and t10,c12 (each at least 36% of CLA-rich oil in Health Canada's specification) [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Studied in trials: 2.4–6 g/day for 6–12 months (seven-trial meta-analysis cited by NIH ODS). [4]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
NIH ODS: CLA has been linked to hepatitis in three case reports, without confirmed causation.
Details and sources - Pregnancy and breastfeedingHealth Canada's CLA monograph: do not use if pregnant; ask a health care practitioner before use if breastfeeding.
2 statements in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Canada (Health Canada CLA monograph, January 10, 2025), adults 18 years and older: 3–5 g CLA per day (about 4–6.5 g CLA-rich oil) …
Details and sources
- NIH ODS: CLA appears to be well tolerated; most reported adverse effects are minor, mainly gastrointestinal disturbances such as abdominal discomfort and pain, constipation, diarrhea, loose stools, nausea, vomiting and dyspepsia. [4]
- NIH ODS: CLA has been linked to hepatitis in three case reports; whether CLA caused this cannot be definitively established because the products were not analyzed to rule out a contaminant. [4]
- NIH ODS: t10,c12-CLA has been reported to increase insulin resistance and glycemia in men with obesity; CLA might also increase some markers of oxidative stress and decrease breast milk fat levels. [4]
- A 2023 meta-analysis of 13 RCTs in people at risk of cardiovascular disease found CLA raised fasting blood glucose by 4.49 mg/dL and AST by 2.54 IU/L, with no effect on HbA1c or HOMA-IR; the authors called the changes small. [5]
- Health Canada's CLA monograph: do not use if pregnant, or with cardiovascular disease, diabetes, metabolic syndrome or insulin resistance; ask a practitioner before use if breastfeeding, obese or with cardiovascular risk factors, and for use beyond 6 months. [1]
Identity, quality and standardization
- Health Canada specification for CLA-rich oil: total CLA at least 78%; c9,t11 plus t10,c12 isomers at least 74%; each of these at least 36%; trans,trans isomers 3% or less; peroxide value no more than 1 meq O2/kg to ensure oxidative stability. [1]
Regulatory status
- US: FDA had no questions about GRAS Notices 232 (closed July 11, 2008) and 521 (closed December 8, 2014) for conjugated linoleic acid isomers as ingredients in specified foods; FDA ceased to evaluate two earlier CLA notices (148, 153) at the notifiers' request. These concern food uses. [6]
- Canada: Health Canada's CLA monograph (January 10, 2025) permits claims that CLA may help support a modest reduction in fat mass or improvement in body composition when used with reduced calorie intake and increased physical activity. [1]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Conjugated linoleic acid isomers c9,t11 and t10,c12 Fatty acids and lipids (conjugated fatty acid isomers) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 3 entries naming conjugated linoleic acid (earliest NDI 160 submitted 2002-06-17; most recent NDI 650 submitted 2010-04-13). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
- GRAS: FDA's GRAS Notice Inventory lists 4 notices for conjugated linoleic acid: FDA had no questions for GRN 232 (closed July 11, 2008) and GRN 521 (closed December 8, 2014), and ceased to evaluate GRN 148 and 153 at the notifiers' request. GRAS notices concern food uses. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]
- CLA isomer profile (total CLA, c9,t11, t10,c12, trans,trans) — Health Canada's specification: total CLA at least 78%, c9,t11 and t10,c12 each at least 36%, trans,trans 3% or less. [P1]
- Peroxide value (no more than 1 meq O2/kg), by AOCS and/or pharmacopoeial methods — Health Canada states this specification is necessary to ensure the oxidative stability of CLA. [P1]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Canada (Health Canada CLA monograph, January 10, 2025), adults 18 years and older: 3–5 g CLA per day (about 4–6.5 g CLA-rich oil); ask a health care practitioner for use beyond 6 months. [P1]
Sources for this profile
- Health Canada NNHPD. Natural health product monograph: Conjugated Linoleic Acid (date January 10, 2025), 2025-01-10. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory (downloaded export; inventory last updated 10/21/2026; downloaded 10/29/2026), 2026-10-21. hfpappexternal.fda.gov
- IARC Monographs. List of Classifications, Volumes 1–142 (list data dated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- NIH Office of Dietary Supplements. Dietary Supplements for Weight Loss: Fact Sheet for Health Professionals (no printed update date captured; page last modified 2026-10-22 per page metadata), 2026-10-22. ods.od.nih.gov
- Ghodoosi N, et al. The effects of conjugated linoleic acid supplementation on glycemic control, adipokines, cytokines, malondialdehyde and liver function enzymes in patients at risk of cardiovascular disease: a GRADE-assessed systematic review and dose-response meta-analysis. Nutr J 2023;22(1):47 (PMID 37794481), 2023-10. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/28/2026), 2026-10-28. ecfr.gov
Sources
- Health Canada NNHPD. Natural health product monograph: Conjugated Linoleic Acid (date January 10, 2025), 2025-01-10. webprod.hc-sc.gc.ca
- Asbaghi O, et al. The effects of conjugated linoleic acid supplementation on anthropometrics and body composition indices in adults: a systematic review and dose-response meta-analysis. Br J Nutr 2024;131(3):406-428 (PMID 37671495), 2024-02. pubmed.ncbi.nlm.nih.gov
- Onakpoya IJ, et al. The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials. Eur J Nutr 2012;51(2):127-34 (PMID 21990002), 2012-03. pubmed.ncbi.nlm.nih.gov
- NIH Office of Dietary Supplements. Dietary Supplements for Weight Loss: Fact Sheet for Health Professionals (no printed update date captured; page last modified 2026-10-22 per page metadata), 2026-10-22. ods.od.nih.gov
- Ghodoosi N, et al. The effects of conjugated linoleic acid supplementation on glycemic control, adipokines, cytokines, malondialdehyde and liver function enzymes in patients at risk of cardiovascular disease: a GRADE-assessed systematic review and dose-response meta-analysis. Nutr J 2023;22(1):47 (PMID 37794481), 2023-10. pubmed.ncbi.nlm.nih.gov
- FDA. GRAS Notice Inventory (downloaded export; inventory last updated 10/21/2026; downloaded 10/29/2026), 2026-10-21. hfpappexternal.fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in fatty acid: Algal oil (DHA and EPA) · Arachidonic acid · Argan oil · Evening primrose oil · GLA oils (borage and blackcurrant seed oil) · Krill oil · Linoleic acid · MCT oil (medium-chain triglycerides) · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.